According to Alexandria Real Estate Equities 's latest financial reports the company's current earnings (TTM) are $0.35 B. In 2022 the company made an earning of $0.76 B a decrease over its 2021 earnings that were of $0.79 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | $0.35 B | -53.56% |
2022 | $0.76 B | -3.96% |
2021 | $0.79 B | -20.26% |
2020 | $0.99 B | 72.88% |
2019 | $0.57 B | 3.11% |
2018 | $0.56 B | 73.54% |
2017 | $0.32 B | 464.88% |
2016 | $57.15 M | -77.32% |
2015 | $0.25 B | 36.31% |
2014 | $0.18 B | -10.81% |
2013 | $0.20 B |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | 819.77% | ๐บ๐ธ USA |
Eli Lilly LLY | $6.55 B | 1,745.34% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | 2,111.44% | ๐บ๐ธ USA |
Gilead Sciences GILD | $6.85 B | 1,831.04% | ๐บ๐ธ USA |
Illumina ILMN | -$1.04 B | -392.79% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | 2,276.14% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -$0.32 B | -187.92% | ๐บ๐ธ USA |